查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1935472

全球血液篩檢市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Blood Screening Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 114 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計血液篩檢市場規模將從 2025 年的 38.8 億美元成長到 2034 年的 113.1 億美元，2026 年至 2034 年的複合年成長率為 12.62%。

由於感染疾病流行以及對安全輸血的需求不斷成長，血液篩檢市場預計將迎來顯著成長。血液篩檢是確保血液製品安全的關鍵流程，它透過檢測病原體、抗體和其他有害物質來實現這一目標。隨著醫療機構將病患安全放在首位，監管機構也加強了檢測要求，先進血液篩檢技術的應用預計將會增加。市場正朝著更有效率、更準確的檢測方法轉變，例如核酸檢測 (NAT) 和多重檢測，這些方法提高了血液篩檢的檢測能力。

此外，血液篩檢技術的進步正在推動市場創新。自動化系統和就地檢驗解決方案的開發正在改變血液篩檢的方式，從而加快檢測速度並提高工作流程效率。這些創新不僅提高了檢測準確性，還縮短了結果週轉時間，使醫療服務提供者能夠及時做出有關患者照護的決策。隨著血液篩檢市場的不斷發展，持續的研發工作將在拓展檢測解決方案範圍以滿足醫療服務提供者多樣化需求方面發揮關鍵作用。

此外，對預防性醫療保健和早期檢測的日益重視正在重塑血液篩檢模式。隨著人們對定期健康檢查重要性的認知不斷提高，患者越來越傾向於進行血液檢測，以便在潛在健康問題惡化之前將其識別出來。醫療保健提供者也認知到主動篩檢在慢性病管理和改善患者預後的價值。隨著血液篩檢市場的持續成長，技術進步、患者意識的提高以及對預防性醫療保健的重視將在推動未來成長方面發揮關鍵作用。

目錄

第1章 引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 繪製滲透率和成長前景圖
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制
    • 市場機遇
    • 市場問題
  • 波特五力分析
  • PESTLE分析

4. 全球血液篩檢市場（依技術分類）

  • 市場分析、洞察與預測
  • 核酸增幅檢查（NAT）
  • ELISA
  • 化學冷光免疫檢測（CLIA 和 EIA）
  • 次世代定序（NGS）
  • 蛋白質印跡法（WB）

5. 全球血液篩檢市場（依產品分類）

  • 市場分析、洞察與預測
  • 試劑
  • 裝置

6. 全球血液篩檢市場（按地區分類）

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第7章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商格局（基於現有資訊）
  • 策略規劃

第8章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Abbott
    • Danaher Corporation（Beckman Coulter）
    • Becton Dickinson And Company
    • Bio-Rad LaboratoriesInc
    • Hoffman-La Roche Ltd
    • Grifols, SA
    • Ortho-Clinical DiagnosticsInc
    • Siemens Healthcare GmbH
    • Thermo Fisher ScientificInc
    • SOFINA SA（Biomerieux）
簡介目錄
Product Code: VMR11210532

The Blood Screening Market size is expected to reach USD 11.31 Billion in 2034 from USD 3.88 Billion (2025) growing at a CAGR of 12.62% during 2026-2034.

The blood screening market is poised for significant growth, driven by the increasing prevalence of infectious diseases and the rising demand for safe blood transfusions. Blood screening is a critical process that ensures the safety of blood products by detecting pathogens, antibodies, and other harmful substances. As healthcare providers prioritize patient safety and regulatory bodies enforce stringent testing requirements, the adoption of advanced blood screening technologies is expected to rise. This market is witnessing a shift towards more efficient and accurate testing methods, including nucleic acid testing (NAT) and multiplex assays, which enhance the detection capabilities of blood screening processes.

Moreover, advancements in blood screening technologies are propelling innovation within the market. The development of automated systems and point-of-care testing solutions is transforming the way blood screening is conducted, allowing for faster results and improved workflow efficiency. These innovations not only enhance the accuracy of testing but also reduce the turnaround time for results, enabling healthcare providers to make timely decisions regarding patient care. As the blood screening market continues to evolve, ongoing research and development efforts will play a crucial role in expanding the range of testing solutions available to meet the diverse needs of healthcare providers.

Additionally, the growing emphasis on preventive healthcare and early detection is shaping the blood screening landscape. As awareness of the importance of regular health screenings increases, patients are more likely to seek out blood tests that can identify potential health issues before they escalate. Healthcare providers are also recognizing the value of proactive screening in managing chronic conditions and improving patient outcomes. As the blood screening market continues to grow, the combination of technological advancements, increasing patient awareness, and a focus on preventive care will play a crucial role in driving its future growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Technology

  • Nucleic Acid Amplification Test (NAT)
  • ELISA
  • Chemiluminescence Immunoassay (CLIA & EIA )
  • Next Generation Sequencing (NGS)
  • Western Blotting (WB)

By Product

  • Reagent
  • Instrument

COMPANIES PROFILED

  • Abbott, Danaher Corporation Beckman Coulter, Becton Dickinson and Company, BioRad Laboratories, Inc, HoffmanLa Roche Ltd, Grifols, SA, OrthoClinical Diagnostics, Inc, Siemens Healthcare GmbH, Thermo Fisher Scientific, Inc, SOFINA sa Biomerieux

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL BLOOD SCREENING MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Technology
  • 4.2. Nucleic Acid Amplification Test (NAT) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. ELISA Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Chemiluminescence Immunoassay (CLIA & EIA ) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Next Generation Sequencing (NGS) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Western Blotting (WB) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BLOOD SCREENING MARKET: BY PRODUCT 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Product
  • 5.2. Reagent Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Instrument Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BLOOD SCREENING MARKET: BY REGION 2022-2034(USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Technology
    • 6.2.2 By Product
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Technology
    • 6.3.2 By Product
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Technology
    • 6.4.2 By Product
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Technology
    • 6.5.2 By Product
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 South East Asia
    • 6.5.8 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Technology
    • 6.6.2 By Product
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL BLOOD SCREENING INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 Abbott
    • 8.2.2 Danaher Corporation (Beckman Coulter)
    • 8.2.3 Becton Dickinson And Company
    • 8.2.4 Bio-Rad LaboratoriesInc
    • 8.2.5 Hoffman-La Roche Ltd
    • 8.2.6 Grifols, S.A
    • 8.2.7 Ortho-Clinical DiagnosticsInc
    • 8.2.8 Siemens Healthcare GmbH
    • 8.2.9 Thermo Fisher ScientificInc
    • 8.2.10 SOFINA S.A (Biomerieux)